Quick Answer
Caribou Biosciences, Inc. reported Total Revenue of $11.16 million for fiscal year 2025.
Caribou Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $11.16M +11.7% |
$9.99M -71.0% |
$34.48M +148.9% |
$13.85M +44.3% |
$9.60M -22.4% |
$12.36M +113.6% |
| Revenue (ASC 606) | $11.16M +11.7% |
$9.99M -71.0% |
$34.48M +148.9% |
$13.85M +44.3% |
$9.60M -22.4% |
$12.36M +113.6% |
| Net Income | -$148.12M +0.7% |
-$149.10M -46.1% |
-$102.07M -2.7% |
-$99.42M -48.6% |
-$66.92M -95.1% |
-$34.31M -46.4% |
| Diluted EPS | -$1.59 +3.6% |
-$1.65 -19.6% |
-$1.38 +15.9% |
-$1.64 +22.3% |
-$2.11 | — |
| Total Assets | $175.37M -44.0% |
$313.31M -27.5% |
$432.21M +15.6% |
$373.76M -15.5% |
$442.36M +1127.2% |
$36.05M |
| Cash and Equivalents | $12.36M -24.1% |
$16.29M -68.2% |
$51.16M -12.3% |
$58.34M -75.7% |
$240.42M +1407.1% |
$15.95M -61.2% |
| Stockholders Equity | $122.17M -51.7% |
$252.95M -31.3% |
$368.40M +22.4% |
$300.87M -22.4% |
$387.82M +1754.8% |
-$23.44M -414.0% |
| R&D Expense | $109.44M -15.9% |
$130.15M +16.1% |
$112.08M +36.3% |
$82.23M +57.4% |
$52.26M +51.8% |
$34.42M +45.7% |
| Operating Income | -$148.34M +11.0% |
-$166.62M -43.6% |
-$116.06M -9.1% |
-$106.40M -58.9% |
-$66.98M -85.4% |
-$36.12M -5.3% |
| Shares Outstanding | 95.14M +3.0% |
92.38M +4.4% |
88.45M +44.9% |
61.03M +1.3% |
60.26M +520.6% |
9.71M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.20M | +8.6% | -17.6% |
| Revenue (ASC 606) | September 30, 2025 | $2.20M | +8.6% | -17.6% |
| Net Income | September 30, 2025 | -$27.55M | +20.6% | +49.1% |
| Diluted EPS | September 30, 2025 | -$0.30 | +21.1% | +48.3% |
| Total Assets | September 30, 2025 | $194.98M | -43.4% | -11.7% |
| Cash and Equivalents | September 30, 2025 | $11.14M | -65.1% | -55.8% |
| Stockholders Equity | September 30, 2025 | $141.84M | -49.6% | -14.6% |
| R&D Expense | September 30, 2025 | $22.40M | -26.4% | -19.1% |
| Operating Income | September 30, 2025 | -$29.40M | +23.1% | +38.2% |
| Shares Outstanding | September 30, 2025 | 93.47M | +3.2% | +0.4% |
- Caribou Biosciences, Inc. reported Total Revenue of $11.16 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed an increase of +11.7% in Total Revenue compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Revenue (ASC 606) of $11.16 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed an increase of +11.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Net Income of -$148.12 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed an increase of +0.7% in Net Income compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Diluted EPS of $1.59 per share (loss) for fiscal year 2025.
- Caribou Biosciences, Inc. showed an increase of +3.6% in Diluted EPS compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Total Assets of $175.37 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed a decrease of -44.0% in Total Assets compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Cash and Equivalents of $12.36 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed a decrease of -24.1% in Cash and Equivalents compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Stockholders Equity of $122.17 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed a decrease of -51.7% in Stockholders Equity compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported R&D Expense of $109.44 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed a decrease of -15.9% in R&D Expense compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Operating Income of -$148.34 million for fiscal year 2025.
- Caribou Biosciences, Inc. showed an increase of +11.0% in Operating Income compared to the prior fiscal year.
- Caribou Biosciences, Inc. reported Shares Outstanding of 95.14 million shares for fiscal year 2025.
- Caribou Biosciences, Inc. showed an increase of +3.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: